News › Clinical Practice, Industry News, Patient Care

A Novel Formulation for Investigational Botulinum Toxin A

October 22, 2019

Swiss healthcare company Galderma has announced the phase 2 clinical trial results for its liquid formulation of investigational botulinum toxin, QM1114. The study—conducted as multi-center, randomized, double-blind and placebo-controlled—successfully showcased the safety and efficacy of botulinum toxin type A, according to the company.
“Toxin treatment-naive subjects aged ≥18 years with moderate-to-very severe GLs [glabellar lines] at maximum frown and at least mild GLs at rest were eligible for this multi-centre, double-blind 6-month Phase II study,” according to the abstract from the oral presentation on the subject at the 24th World Congress of Dermatology, Milan.
Read more at Dermatology Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available